// App-Quantinova.ai

339 : Efficacy and Safety of Zanubrutinib in Patients with Relapsed/Refractory Marginal Zone Lymphoma: Initial Results of the MAGNOLIA (BGB-3111-214) Trial

Researchers

Presenter

  • Stephen Opat

Principal Investigators

  • Kim Linton

  • Pamela McKay

  • Bei Hu

  • Henry Chan

  • Jie Jin

  • Pier Luigi Zinzani

  • Peter Browett

  • Morton Coleman

  • Magdalena Sobieraj-Teague

  • Xiaoyan Ke

  • Mingyuan Sun

  • Robert Marcus

  • Craig A. Portell

  • Keshu Zhou

  • Catherine Thieblemont

  • Melannie Co

  • Weige Wang

  • Chris Tankersley

  • Wenxiao Zhou

  • Massimo Cappellini

  • Jane Huang

  • Judith Trotman

Medical Centers

  • Deakin University, Melbourne, Australia

  • Monash Health, Clayton, Australia

  • Grande Ospedale Metropolitano Niguarda, Milan, Italy

  • The Christie Hospital, Manchester, United Kingdom

  • Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom

  • Levine Cancer Institute, Atrium Health, Charlotte, NC

  • North Shore Hosp, Auckland, New Zealand

  • The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, China

  • Institute of Hematology, University of Bologna, Bologna, Italy

  • Auckland City Hospital, Auckland, New Zealand

  • Clinical Research Alliance, Lake Success, NY

  • Flinders Medical Centre, Bedford Park, Australia

  • Peking University Third Hospital Beijing China

  • Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Science & Peking Union Medical College, Tianjin, China

  • Sarah Cannon Research Institute, London, United Kingdom

  • University of Virginia Medical Center, Charlottesville, VA

  • Henan Cancer Hospital, Zhengzhou, China

  • APHP, Hôpital Saint-Louis, Hemato-oncology, Paris University Diderot, Paris, France

  • BeiGene (Beijing) Co., Ltd., Beijing, China and BeiGene USA, Inc.,San Mateo, CA,Vereinigte Staaten

  • University of Sydney, St. Leonards, Australia

  • Concord Repatriation General Hospital, Concord, NSW, Australia

Locations

  • Australia

  • Italy

  • United Kingdom

  • United States

  • New Zealand

  • China

  • France

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Mucosa-associated lymphoid tissue lymphoma

Biomarkers

  • N/A

Drug/Treatment

  • BGB-3111

Outcome

  • N/A

Study Design

  • Single Arm

  • Multicenteric

Phase

  • II

Study Id's

  • NCT03846427

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved